Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PRS.0000000000003092 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PD-L1 Expression for Tailoring Treatment in Advanced Melanoma-It Is Never That Easy-Reply.
JAMA Oncol
November 2024
National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.
A reply to: 'Melanoma documented arising in an involuting naevus 3 years after cessation of monitoring'.
Australas J Dermatol
November 2024
Department of Dermatology, Mater Hospital, Brisbane, Queensland, Australia.
Reply to: "Methodological Concerns Regarding: "Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?"" by Ahlström.
Ann Surg Oncol
January 2025
Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Reply to: Pioneering combination: Nivolumab and isolated limb perfusion in melanoma in-transit metastases treatment.
Eur J Surg Oncol
December 2024
Sahlgrenska University Hospital, Department of Surgery, Gothenburg, Sweden; Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden. Electronic address:
Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma-What's in a Name?-Reply.
JAMA Dermatol
October 2024
Division of Dermatology, Dell Medical School, University of Texas at Austin.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!